TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* written informed consent to the study~* age \>= 55 years at randomization. There is no upper age limit~* systolic blood pressure \>= 150 mmHg in 2 visits at distance of 7-14 days, irrespective of diastolic pressure. Duration of treatment before visit 1 must be at least 12 weeks~* at least one additional risk factor including the following:~* current cigarette smoking~* total cholesterol \>= 20 mmg/dl, or High Density Lipoproteins (HDL) \< 40 mg/dl, or Low Density Lipoproteins (LDL) cholesterol \>= 130 mg/dl~* family history of cardiovascular disease in male first degree relative \< 55 years or female first degree relative \< 65 years~* previous TIA or stroke~* previous coronary artery disease~* history of peripheral occlusive arterial disease (claudication intermittens associated with angiographic or echographic evidence of \> 60% stenosis)~Exclusion Criteria:~* diabetes (fasting glucose \> 125 mg/dl in two samples or ongoing diabetic treatment)~* renal failure, defined by a serum creatinine \> 2.0 mg/dl~* chronic atrial fibrillation or flutter~* clinically significant hepatic or hematological disorders, alcoholism, drug addiction~* causes precluding ECG interpretation for LVH: complete right or left bundle block, Wolff-Parkinson-White syndrome, previous Q-wave myocardial infarction~* any disease causing reduced life expectancy~* unwilling to participate~* significant (more than traces of) valvular heart disease

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intensive Strategy (Type: OTHER): None
- Usual Strategy (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Insulin Glargine Dosing Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for Surgical Procedure~* Self Management of Diabetes~* Currently on Evening Insulin Glargine prescribed by Primary Care Physician~* Age 18 or over~* Able to Communicate Clearly over the Phone~* Pre-screened by Anesthesia Department \> 48 hours prior to Surgery~Exclusion Criteria:~* On Glucocorticoid Medication~* On Insulin Glargine Dual Dosing or Sliding Scale Regimen~* History of Hypoglycemia Unawareness~* Pregnancy or Lactating Female~* On Insulin Glargine for \< 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Patients in Group 1 will administer 80% of their usual insulin glargine dose.
- 2 (Type: ACTIVE_COMPARATOR): Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose.
- 3 (Type: EXPERIMENTAL): Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years or older~2. Diagnosis of primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF~3. Enlarged spleen, measuring 5 cm or greater from the costal margin~4. Must have two or more of the following risk factors:~   1. Over 65 years old~  2. Have the following symptoms often associated with MF: loss of weight, fever, night sweats~  3. Have a low red blood cell count (anemia - hemoglobin \< 10 g/dL)~  4. Have a high white blood cell count (history of white blood cell count \> 25,000/uL)~  5. Have high circulating blasts (\> or = 1%) as measured by blood tests~5. Should have circulating blasts \<10% (as measured by blood tests)~6. Should be capable of self-care~7. Should have adequate bone marrow reserve~8. Should not have the option of stem cell transplantation~9. Should discontinue any prior or ongoing treatment for myelofibrosis prior to entering the study~10. Had no prior treatment with another JAK inhibitor~Exclusion Criteria:~1. Does not have adequate liver or kidney function (as measured by blood tests)~2. Has an active infection (bacterial, viral, etc.)~3. Has active hepatitis A, B, or C or positive for HIV~4. Has another cancer that needs active intervention~5. Had a history of bleeding disorder~6. Had a history of very low platelet counts (as measured by blood tests) not related to treatment of MF~7. Had radiation of the spleen within 1 year of joining the study~8. Does not have adequate heart function~9. Sufficient time has elapsed between stopping previous treatment for MF and joining the study~10. Females who are pregnant or breast-feeding~11. Not able to sign informed consent~12. Has any other active medical conditions that the doctor deems may compromise your safety or ability to join in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib (Type: EXPERIMENTAL): Ruxolitinib was taken twice daily, unless instructed. Starting dose 15 mg BID for patients with baseline platelet count of 100,000/μL to 200,000/μL (inclusive) or 20 mg BID for those with baseline platelet count \>200,000/μL (approximately 12 hours apart: morning and night), increased or decreased per standardized dosing paradigm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Patients with active acromegaly (based on elevated GH and IGF-1 levels)~* Patients who have undergone one or more pituitary surgeries, but have not been treated medically, or de-novo patients presenting a visible pituitary adenoma on MRI and who refuse pituitary surgery or for whom pituitary surgery is contraindicated~* Patients for whom written informed consent to participate in the study has been obtained prior to any study related activity~Exclusion criteria:~* Patients who are being or were treated with octreotide, lanreotide, dopamine agonists or GH antagonists with the exception of a single dose of short-acting octrotide or short-acting dopamine agonists. In case of a single dose of short-acting octrotide, the dose should not be used to predict the response to the octretide treatment. The single dose of short-acting octreotide or short-acting dopamine agonists should not be administered in the 3 days prior to randomization~* Patients with compression of the optic chiasm causing any visual field defect~* Patients who have received pituitary irradiation within the last ten years prior to visit 1~* Poorly controlled diabetic patients~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pasireotide LAR (Type: EXPERIMENTAL): Patients in this arm received Pasireotide LAR 40 mg im depot injection, blinded, once every 28 days (± 2 days) for 12 months. Dose could be down- or up-titrated to 20 or 60 mg, respectively. Patients who responded to Pasireotide LAR (i.e. the randomized treatment) at the end of the core (Month 12), continued Pasireotide LAR treatment in the extension. Patients who did not respond to Pasireotide LAR at the end of the core (Month 12) were allowed to switch to receive Octreotide LAR in the extension.
- Octreotide LAR (Type: ACTIVE_COMPARATOR): Patients in this arm received Octreotide LAR 20 mg im depot injection, blinded, once every 28 days (± 2 days) for 12 months. Dose could be down- or up-titrated to 10 or 30 mg, respectively. Patients who responded to Octreotide LAR (i.e. the randomized treatment) at the end of the core (Month 12) continued Octreotide LAR treatment in the extension (up to 2 years of treatment). Patients who did not respond to Octreotide LAR at the end of the core (Month 12) were allowed to switch to receive Pasireotide LAR in the extension.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Continuous Negative External Pressure in Preventing Upper Airway Impairment During Routine Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects undergoing elective colonoscopy at the Study Site who have fewer than three or more than three positive responses on the STOP BANG questionnaire~Exclusion Criteria:~* Presence of severe cardiopulmonary or neurologic disease as determined by the investigator~* History of vascular fragility associated with cutaneous pressure~* History of hypersensitivity to silicone~* Inability to properly fit cNEP collar to the subject~* The presence of excessive facial hair in the region where the cNEP collar is positioned~* Known carotid vascular disease, previous major neck surgery or radiation therapy to the cervical region~* Presence of anatomical abnormalities in the neck or pharyngeal region (such as enlarged tonsils)~* Inability to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- active cNEP @ -45cmw (Type: EXPERIMENTAL): cNEP @ -45 cmw is applied to the anterior surface of the neck with a soft collar attached to a vacuum source.
- no intervention (Type: NO_INTERVENTION): Routine care is administered without the application of cNEP.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Michelangelo - Oasis 5

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting or admitted to hospital with symptoms suspected to represent an acute coronary syndrome.~* Able to randomize within 24 hours of the onset of the most recent episode of symptoms.~* At least one of the following additional criteria: (1) Troponin T of I or CK-MB above the upper limit of normal for the local institution and/or (2) ECG changes compatible with ischemia~* Written informed consent~Exclusion Criteria:~* Age \< 21 years~* Any contraindication to low molecular weight heparin~* Hemorrhagic stroke within the last 12 months~* Indication for anticoagulation other than ACS.~* Pregnancy or women of childbearing potential who are not using an effective method of contraception~* Co-morbid condition with life expectancy less than 6 months~* Prior enrollment in one of the fondaparinux ACS trails or currently receiving an experimental pharmacologic agent

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enoxaparin (Type: ACTIVE_COMPARATOR): None
- Fondaparinux (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese participant~* Age 6 weeks through \<11 weeks (42 to 76 days from date of birth) at Visit 1~Exclusion Criteria:~* History of hypersensitivity and/or anaphylaxis to any of the product ingredients in V260 or DTP-IPV~* Gastrointestinal disorder, growth retardation, or failure to thrive~* History of intussusception~* Untreated congenital gastrointestinal disorder (such as Meckel diverticulum)~* Known or suspected impairment of immunological function, including severe immunodeficiency (SCID)~* Cardiovascular, renal, liver, or blood disease~* History of convulsion~* Undergoing immunosuppressive therapy or living with a close relative with congenital immune deficiency~* Prior vaccination with rotavirus vaccine and/or DTP-IPV vaccine~* Live vaccine received within 28 days or inactivated vaccine received within 7 days~* At high risk for tuberculosis exposure

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 11 Weeks
- Healthy Volunteers: t

Study Arms:
- Concomitant RotaTeq™ and DTP-IPV (Type: EXPERIMENTAL): RotaTeq™ (2 mL oral dose) and DTP-IPV (0.5 mL subcutaneous injection) administered concomitantly at Visit 2 (\>=4 weeks after Visit 1), Visit 4 (6-8 weeks after Visit 2), and Visit 6 (6-8 weeks after Visit 4).
- Staggered RotaTeq™ and DTP-IPV (Type: ACTIVE_COMPARATOR): RotaTeq™ (2 mL oral dose) administered at Visit 1 (Day 1), Visit 3 (6-8 weeks after Visit 1), and Visit 5 (6-8 weeks after Visit 3) and DTP-IPV (0.5 mL subcutaneous injection) administered at Visit 2 (\>=4 weeks after Visit 1), Visit 4 (6-8 weeks after Visit 2), and Visit 6 (6-8 weeks after Visit 4).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Integrated Program for the Treatment of First Episode of Psychosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed SCID DSM-IV clinical diagnosis by trained remote clinical assessor of:~  * schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, psychotic disorder NOS~* Any duration of untreated psychosis~* Any ethnicity~* Ability to participate in research assessments in English~* Ability to provide fully informed consent (assent for those under age 18)~Exclusion Criteria:~* Inability to understand what research participation entails or correctly answer the questions about research participation that are part of the Study Information Review and provide fully informed consent~* More than 4 months of prior cumulative treatment with antipsychotic medications~* Diagnosis of bipolar disorder, psychotic depression or substance-induced psychotic disorder~* Current psychotic disorder due to a general medical condition~* Current neurological disorders that would affect diagnosis or prognosis. These would include, but are not limited to seizure disorders, dementing or degenerative disorders, lesions or substantial congenital abnormalities. In most cases, disorders such as headache disorders would not require protocol exclusion~* Clinically significant head trauma~* Any other serious medical condition that in the opinion of the investigator would seriously impair functioning making the patient unsuitable for the trial

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Integrated Treatment (Type: EXPERIMENTAL): Integrated program of treatments and services delivered by a coordinated team of providers.
- Community Care (Type: ACTIVE_COMPARATOR): Standard mental health treatments and services offered at the local agency.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Age 18 or greater with a confirmed diagnosis of homozygous SCD (HbSS, HbSC, HbSB0), sickle cell trait (HbAS), or healthy volunteer (HbA)~* Normal renal function: creatinine \<1.5 mg/dL~* Negative direct antiglobulin test (DAT)~* Ability to give informed consent to participate in the protocol~EXCLUSION CRITERIA:~* Any uncontrolled chronic illness other than sickle cell disease~* Active viral, bacterial, fungal, or parasitic infection~* Consumption of biotin supplements or raw eggs within 30 days~* Blood loss within the previous 8 weeks \>540mL~* Pregnancy~* Pre-existing, naturally occurring antibodies against biotin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- Sickle Cell Disease Pre-Transplantation (Type: EXPERIMENTAL): Autologous cells will be collected in participants with Sickle Cell Disease Pre-Transplantation and biotin-labeled ex vivo and reinfused to measure red cell survival
- Sickle Cell Disease Post-Transplantation (Type: EXPERIMENTAL): Autologous cells will be collected in participants with Sickle Cell Disease Post-Transplantation and biotin-labeled ex vivo and reinfused to measure red cell survival
- Sickle Cell Trait (HbAS) (Type: EXPERIMENTAL): Autologous cells will be collected in participants with Sickle Cell Trait (HbAS) and biotin-labeled ex vivo and reinfused to measure red cell survival
- HbAA (Healthy volunteers) (Type: EXPERIMENTAL): Autologous cells will be collected in participants with HbAA (Healthy volunteers) and biotin-labeled ex vivo and reinfused to measure red cell survival

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase IIIB Subcutaneous Missed Dose Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Rheumatoid Arthritis~* Disease Activity Score (DAS)28-C-Reactive Protein (CRP) score ≥ 3.2 and ≤5.1~* On background methotrexate at least 3 months (≥10mg weekly)~* Must be able to self injection or allow a care giver to do it for them~* Discontinue all Biologics and Disease-Modifying Anti-rheumatic Drugs (DMARDs) except for methotrexate~Exclusion Criteria:~* Participants who had prior exposure to abatacept or CTLA-4 Ig~* Received treatment with rituximab.~* Participants who have received treatment with leflunomide within 1 year of screening~* Participants who have received treatment with immunoadsorption columns (such as Prosorba columns), mycophenolate mofetil (Cellcept®), cyclosporine A or other calcineurin inhibitors, or D-Penicillamine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abatacept (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
* Children, 3 months through 17 years of age,~* with esophageal candidiasis or~* invasive candidiasis or~* children requiring salvage treatment of invasive aspergillosis.

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HCV viral load~* HCV genotype~* HCV qualitative~* HCV antibody~* HCV drug~* Continuously enrolled 12 months~Exclusion Criteria:~* Each outcome will be analyzed separately as time to first event, thus people who experience an outcome prior to their study start date are ineligible for analyses related to that particular outcome.~The results will be examined for sensitivity to the following possible exclusion criteria:~* Achieved SVR-12 prior to index date~* HCV treatment experienced prior to index date~* No visit in GI, Infectious Disease, or Liver Transplant / Hepatology~* No positive HCV test (genotype, viral load, or qualitative)~* No recent positive HCV test (genotype, viral load or qualitative)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 88 Years
- Healthy Volunteers: None

Study Arms:
- Direct Acting Antivirals (Type: None): Patients who receive a direct acting antiviral enter the DAA cohort at the time of initiation of the drug.
- Comparison (Type: None): The exposure time of patients who have not received a direct acting antiviral (patients can change from the comparison to the DAA group once they receive the medication)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete